Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
February 9, 2024
Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796
Peter Thornton, Valérie Reader, Zsofia Digby, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 17, 2005
Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis
Eugene T Grygielko, William M Martin, Christopher Tweed, et al.
Bio-Protocol
|
June 13, 2017
Isolation and Cultivation of Primary Brain Endothelial Cells from Adult Mice
Julian Christopher Assmann, Kristin Müller, Jan Wenzel, et al.
ACS Chemical Neuroscience
|
January 26, 2026
Ester Prodrug NLRP3 Inflammasome Inhibitor NT-0796 is Brain Active due to Activation by Local Expression of Carboxylesterase-1
Zsofia Digby, Christine Diamond, Heather Wescott, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 5, 2012
Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA
Charlotte Allen, Peter Thornton, Adam Denes, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
August 12, 2025
Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease
Nicholas Clarke, Peter Thornton, Valérie Reader, et al.
Scientific Reports
|
February 22, 2018
Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage
Ian C Scott, Jayesh B Majithiya, Caroline Sanden, et al.
Cephalalgia : an International Journal of Headache
|
November 2, 2020
Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine
Caroline M Kopruszinski, Peter Thornton, Joanne Arnold, et al.
Pain
|
January 20, 2018
Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain
Louise S C Nicol, Peter Thornton, Jon P Hatcher, et al.
RSC Medicinal Chemistry
|
September 8, 2025
Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an <i>in vivo</i> tool compound for neuroinflammatory disorders
David Harrison, Andy Billinton, Mark G Bock, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
The Journal of Pharmacology and Experimental Therapeutics
|
February 9, 2024
Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796
Peter Thornton, Valérie Reader, Zsofia Digby, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 17, 2005
Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis
Eugene T Grygielko, William M Martin, Christopher Tweed, et al.
Bio-Protocol
|
June 13, 2017
Isolation and Cultivation of Primary Brain Endothelial Cells from Adult Mice
Julian Christopher Assmann, Kristin Müller, Jan Wenzel, et al.
ACS Chemical Neuroscience
|
January 26, 2026
Ester Prodrug NLRP3 Inflammasome Inhibitor NT-0796 is Brain Active due to Activation by Local Expression of Carboxylesterase-1
Zsofia Digby, Christine Diamond, Heather Wescott, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 5, 2012
Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA
Charlotte Allen, Peter Thornton, Adam Denes, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
August 12, 2025
Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease
Nicholas Clarke, Peter Thornton, Valérie Reader, et al.
Scientific Reports
|
February 22, 2018
Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage
Ian C Scott, Jayesh B Majithiya, Caroline Sanden, et al.
Cephalalgia : an International Journal of Headache
|
November 2, 2020
Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine
Caroline M Kopruszinski, Peter Thornton, Joanne Arnold, et al.
Pain
|
January 20, 2018
Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain
Louise S C Nicol, Peter Thornton, Jon P Hatcher, et al.
RSC Medicinal Chemistry
|
September 8, 2025
Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an <i>in vivo</i> tool compound for neuroinflammatory disorders
David Harrison, Andy Billinton, Mark G Bock, et al.
Page
of 3